59338-85-1

Usage

InChI:InChI=1/C9H12N2O3/c1-13-8-4-7(11)6(10)3-5(8)9(12)14-2/h3-4H,10-11H2,1-2H3

Upstream product

• 99459-57-1 2-methoxy-4,5-dinitro-benzoic acid methyl ester 
• 59338-84-0 methyl 4-amino-2-methoxy-5-nitrobenzoate 
• 27492-84-8 Methyl 4-amino-2-methoxybenzoate 
• 4093-41-8 methyl 4-acetamido-2-methoxy-5-nitrobenzoate 
• 4093-29-2 methyl 4-(acetylamino)-o-anisate 
• 186581-53-3 diazomethane 
• 90833-87-7 4,5-di(amino)-2-hydroxybenzoic acid 

Downstream Products

• 59338-86-2 6-methoxy-1H-benzotriazole-5-carboxylic acid methyl ester 

Relevant academic research and scientific papers

ARYL AND HETEROARYL-CARBOXAMIDE SUBSTITUTED HETEROARYL COMPOUNDS AS TYK2 INHIBITORS

Novel carboxamide substituted compounds of Formula (I) are disclosed; as well as processes for their preparation, pharmaceutical compositions comprising them and their use in therapy as inhibitors of Tyrosine Kinase 2 (Tyk2).

ACTIVATORS OF THE RETINOIC ACID INDUCIBLE GENE "RIG-I' PATHWAY AND METHODS OF USE THEREOF

The present invention is directed to compounds of Formula (I), which are activators of the RIG-I pathway.

ACTIVATORS OF THE RETINOIC ACID INDUCIBLE GENE "RIG-I" PATHWAY AND METHODS OF USE THEREOF

The present invention is directed to compounds of Formula (I), which are activators of the RIG-I pathway.

BICYCLIC HETEROARYL DERIVATIVES AS ECTONUCLEOTIDE PYROPHOSPHATASE PHOSPHODIESTERASE 1 INHIBITORS

The present disclosure provides certain bicyclic heteroaryl compounds that inhibit ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1) enzymatic activity and are therefore useful for the treatment of diseases and conditions modulated at least in part by ENPP1. In some embodiments, the bicyclic heteroaryl compounds includes those of Formula (I). Also provided herein are pharmaceutical compositions containing such compounds and processes for preparing such compounds.

As neuroprotective agents of pharmaceutical compounds

The invention discloses a medicinal compound as a neuroprotective agent. The medicinal compound is a neuronal nitric oxide synthase-postsynaptic density protein 95 (nNOS-PSD95) decoupling agent. The medicinal compound is a benzene ring derivative shown in the general formula (I) or its pharmaceutically acceptable salt. The invention further discloses a preparation method of the medicinal compound and a use of the medicinal compound in prevention and treatment on neuronal damage influence-caused diseases.

N-(1'-Allypyrrolidinyl 2'-methyl) 2-methoxy 4,5-azimido benzamide and its pharmaceutically acceptable salts

The azimido benzamide of this invention and its pharmaceutically acceptable salts have an unusually and unexpectedly high therapeutic index and low toxicity in the treatment of emesis in mammals. Pharmacological testing demonstrated the superior efficacy of the compound of this invention over known, similar compounds.